On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).
|
|
- Rosa Booth
- 6 years ago
- Views:
Transcription
1 31 st March 2015 Submission of comments on ' Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice manufacture of sterile medicinal products EMA/INS/GMP/735037/2014 Comments from: The Pharmaceutical and Healthcare Sciences Society - PHSS On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK). For PHSS Contact: jamesdrinkwater@phss.co.uk (PHSS Chairman) or tamsinmarshall@phss.co.uk (PHSS Operations manager) Please note that these comments and the identity of the sender will be published unless a specific justified objection is received. When completed, this form should be sent to the European Medicines Agency electronically, in Word format (not PDF). 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 1. General comments Stakeholder number Introduction The Pharmaceutical and Healthcare Sciences Society - PHSS would like to offer the following supportive comments to the EMA working group and associated participating authorities working on the concept paper regarding update of EU GMP Annex 1; Guidelines on good manufacturing practice (GMP) of sterile medicinal products. The Pharmaceutical and Healthcare Sciences Society - PHSS fully support the concept for update of GMP Annex 1 and recognise the opportunity such an update presents to correct or clarify current statements as well as to introduce new risk / science based initiatives to the manufacture of sterile products. The drafting of a revised Annex 1 is such an important development that the PHSS as a Not for Profit society involved in GDP/GMP education, preparation of best practice guidance monographs, white papers and regulation change impact papers would welcome an opportunity for contribution, consultation and draft review. It is recognised different working groups are already developing detail point by point recommendations on updates for Annex 1 and these will need review and harmonisation. 2/18
3 The PHSS have shared general points to consider for change of Annex 1 with the A3P working group and in principle the PHSS are in agreement with the general points put forward by A3P. The PHSS consider it useful to focus comment on inclusion of developing concepts; initiatives and principles, that follow the risk based initiatives and scientific approaches but also propose a few detail revisions to consider. The current guideline, including its title, is focused on the manufacture of sterile medicinal products. However, this Annex is the only source of guidance in EU-PIC/S GMP for the conditions of manufacture of some non-sterile finished products and for the early stages in the manufacture of a range of products. In this respect it would be useful to provide clarification on the scope of Annex 1 guidance. Guidance for non-sterile products or materials which are not subsequently used in sterile products potentially varies with guidance on sterile product manufacture hence could benefit a distinct section in Annex 1 or referred to elsewhere in other relevant sections of the GMP. 3/18
4 Some ISO standards are in final revision drafts and have relevance to Annex 1. It is considered important to ensure there is alignment. Examples here include; ISO and ISO classification / reclassification by airborne particles and ISO and ISO (filtration) the latter is especially important as more and more combination products are developed. With the development of aseptic processing, particularly in manufacturing biological products that cannot be terminally sterilised, the requirements for Barrier separation technology, Isolators and RABS Restricted Access Barrier Systems, should be clearly stated in Annex 1. There should be an emphasis in Annex 1 on contamination control where monitoring is used to assess the state of control and instigate investigations following excursions from specified levels and typical/characterised levels of total particulates and microflora in a given process/ facility. 4/18
5 As recognised in the Concept paper it is important to consider new technologies that support new sterile manufacturing / aseptic processing developments and involve new manufacturing practices. In particular it may be useful to cover guidance in use of Single use systems / technologies (disposable sterile components) and use of ready to use sterilised final containers / container closures. Product fluid path systems that are preassembled/ sterilised reducing the amount of aseptic assembly in manufacturing operations require consideration in Annex 1 related to use and introduction to Grade A processing environments. The location of the final sterilising filter in a product delivery path for filling requires consideration in view of new developments. The current GMP text states as close to the point of fill as possible with consideration to reduce downstream aseptic connections. However where CIP/SIP is used the location of the filter, within reason, is less of an issue. Final sterilising filters could be located outside of isolators/ RABS to reduce occluded surfaces, clutter and manipulation inside more restricted Barrier technology where ergonomics can be challenged. The PHSS consider the revised Annex 1 should reflect position of the final sterilising filter when SIP is used. 5/18
6 It may, with justification, also be acceptable to place filling pumps outside an Isolator or RABS on a mobile cart, together with an interconnected product vessel (possibly single use product bag). Such a mobile system would be directly connected to a fluid path sterile connector on the Isolator/ RABS barrier boundary on entry to the Grade A processing zone. If such mobile product transfer carts are used it should be made clear if Grade A air supply is required or not. Where mobile carts are used for Grade A continuity between classified areas it should be made clear if continuous particle monitoring is required during transfer or not. Proposed concepts to be added to Annex 1 Control strategies for manufacture of sterile medicinal products A. The PHSS encourage the inclusion of Control Strategies for manufacture of sterile medicinal products and drug substances. A Control strategy is considered of benefit to regulators, industry/ researchers and ultimately to the patient. Proposed content of Control strategies for sterile product manufacture, has been recently published by the PHSS as a White paper and included as best practice guidance in the PHSS Monograph 20 on the Bio-contamination life cycle (published September 2014). 6/18
7 It is important that throughout the product / process lifecycle that a Control Strategy has been developed and is prepared before entering into the detail of risk assessments. Failure to do so might result in risk levels being under estimated and subsequent risk mitigation being inadequate. An approach to manufacture set out as a Control strategy could become a primary reference in defining the path forward for sterile medicinal product manufacture and the subsequent approach to risk management via applied technical and organisational measures. Proposed structure of Control strategies for sterile medicinal product manufacture: As presented in the PHSS Control strategy White paper such a document should be live, iterative and follow a proactive approach to control in manufacture of sterile medicinal products with consideration to three inextricably linked parts. 7/18
8 1. Approach to risk based manufacturing: detailing product types, processing type e.g. terminally sterilised or aseptically processed, Facility type: multi product or dedicated, material and personnel flows in manufacturing, approach to outsourcing and supply chain together with any special considerations. 2. Listing of Critical Quality Attributes, CQAs, for products to be manufactured and in principle how these will be controlled. 3. Approach to contamination and cross contamination control by technical and organisational measures. 8/18
9 Holistic Environmental monitoring and trend metrics B. With an increasing understanding of the challenges in environmental monitoring using conventional growth based techniques; limitations in sampling and recovery, together with challenging investigations into environmental control excursions or failed sterility tests where the deviation response is purely reactive there is a need to develop more Holistic environmental monitoring programs and trend metrics. Trend metrics could be considered as key performance indicators where incidence rates in deviation above alert and action levels together with incidence rates for OOS; Out of Specification events, related to the critical control parameters and OOT: Out of trend deviations inform on the state of control. Trend metrics provide warning in changes of control conditions and associated increased risk of contamination thereby facilitating a proactive response, possibility before Grade A critical areas become contaminated. The PHSS recommend the introduction of the term Trend metrics into Annex 1 to recognise the importance of trend data and review. 9/18
10 Holistic Environmental monitoring Environmental monitoring (EM) programs trend and compare typical cfu counts and characterised microflora profiles (genus and when required species) across interrelated controlled areas that are under a formal state of control. Areas outside Grade A have measurable cfu counts and typical microflora that can be characterised and identified providing an opportunity to create an area to area profile where a proactive response to risk escalation of Grade A environmental contamination can be initiated as profiles adversely change in surrounding areas. A proactive response would facilitate early investigation and intervention to prevent potential contamination in critical Grade A processing areas where products are exposed to the manufacturing environment. For reference the Holistic environmental monitoring initiative detailed in the PHSS Biocontamination monograph 20 is called; Biocontamination - Risk Profiling and Proactive Response (RPPR). 10/18
11 Like other new technologies, Rapid Micro Methods; RMM, fluorescence based measurement technology is developing to add value to environmental monitoring and inform in real time (RT) on the state of environmental control. In addition use of fluorescence based technologies facilitate no operator intervention monitoring reducing risks in contamination as result of a sampling procedure using growth media/ plates. It would be useful if Annex 1 recognises these developments and In the case of RMM-RT to recognise the different data forms between cfu counts (growth based) and bio-counts (fluorescence based technology: non-growth based). Contamination and Cross contamination control by use of Barrier Separation Technology Contamination and cross contamination control requires implementation of Quality by Design (QbD) principles together with technical and organisational control measures where Holistic monitoring and trend metrics are used to verify the specified state of control is maintained. This linkage is important to current risked based initiatives and would benefit reinforcement in Annex 1. 11/18
12 With the increase in aseptic processing where barrier separation technology is employed it is considered there is a need to reinforce the understanding that barrier separation technology e.g. Isolators and Restricted Access Barrier Systems (RABS) are not an absolute barrier to contamination entry to Grade A process zones. When sterile products are exposed to the Grade A manufacturing environment inside a barrier separation technology system and open system processing is undertaken the surrounding environment, where operators are present, presents a risk as a source of contamination. With the 0cfu level of bio-contamination expected in Grade A environments and the understanding any Barrier separation technology is not an absolute barrier to contamination entry this imposes a necessary mind-set that is sometimes not present in production operations. RABS contamination risks related to operator open barrier door interventions should be addressed in Annex 1. Guidance should be provided on requirements if such open door operator interventions during aseptic processing are proposed by a system user. 12/18
13 Background environments for Isolators and RABS should be proposed in Annex 1 as risk based considering open systems processing where sterile products are exposed to the Grade A processing environment or closed system processing where sterile products are processed in closed containers/ systems inside the Grade A environment. Although for Isolators Grade D is currently stated in EU-GMP as a minimum requirement there is lack of clarity when this minimum is not good practice. In addition there has been some discussion on use of Isolators in non-classified environments. The PHSS do not support this view that non-classified environments are acceptable for Isolators in manufacture of sterile products although in manufacture of non-sterile products where bioburden control is required it may be justified with rationale and possibly some supporting monitoring data. The PHSS consider for Isolators used in aseptic processing of open systems a background environment of Grade C is good practice. For Isolators processing closed systems a background of minimum Grade D is acceptable. For RABS processing open systems the minimum background of Grade B would be considered good practice. RABS processing closed systems e.g. capping, a minimum background of Grade C would be acceptable. 13/18
14 It should be possible to combine Isolators and RABS within the same background environment if processing open systems (in Isolator) and closed systems (in RABS) e.g. Filling Isolator connected to RABS with a capper. Terminology in Annex 1 should be standardised: Standardisation of terminology with international guidelines e.g. Laminar replaced with unidirectional airflow, clean room replaced with cleanroom etc. The PHSS also recommend to replace the general term sanitisation with disinfection. The use of disinfection also aligns with standards/ guidance on disinfectant qualification. 14/18
15 2. Specific comments on text Line number(s) of the relevant text (e.g. Lines 20-23) Stakeholder number (To be completed by the Comment and rationale; proposed changes (If changes to the wording are suggested, they should be highlighted using 'track changes') Outcome General. Section 3 Page 91 Comment: Location required to demonstrate unidirectional airflow and associated velocities As unidirectional air approaches the working zone, it interacts with the machinery and equipment and is also directed towards the extract system and so changes course. Consequently, the determination of an accurate velocity measurement at the working position is dependent upon the test instrument being at the correct orientation with regard to the direction of airflow, which will also vary throughout the zone. A more appropriate method to consistently determine the air velocity is to measure it at a defined distance (typically 15cm) from the HEPA filter face, when it is travelling in the direction of supply before it begins to change direction. The effectiveness of the airflow within the working area should then be determined using airflow visualisation techniques (typically smoke studies). It may also be that velocities higher or lower than that specified in Annex 1 guide are more appropriate or adequate in attaining the required level of operational environmental cleanliness 1 and should be appropriately evaluated and utilised. 15/18
16 Line number(s) of the relevant text (e.g. Lines 20-23) Stakeholder number (To be completed by the Comment and rationale; proposed changes (If changes to the wording are suggested, they should be highlighted using 'track changes') Outcome 1. Eaton T. Cleanroom HVAC and contamination control: A green challenge to the Regulatory (Orange) Guide. Clean Air and Containment Review. Issue 4. October 2010 Proposed change (if any): A more appropriate method to consistently determine the air velocity is to measure it at a defined distance (typically 15cm) from the HEPA filter face, when it is travelling in the direction of supply before it begins to change direction. The effectiveness of the airflow within the working area should then be determined using airflow visualisation techniques (typically smoke studies). Processing. Section 66 Page 101 Comment: Process Simulation Trials With the increased complexity and diversity of aseptic formulation types, the classic use of a nutrient media to replace the formulation within process simulation trials is not always feasible, or scientifically justifiable. Alternative approaches based on risk assessment and scientific rationale could be regarded as equivalent in terms of ensuring an acceptable level of aseptic assurance. Proposed change (if any): In process simulation trials then alternative approaches to use of nutrient media based on risk assessment and scientific rationale could be regarded as equivalent in terms of ensuring an acceptable level of aseptic assurance. 16/18
17 Line number(s) of the relevant text (e.g. Lines 20-23) Stakeholder number (To be completed by the Comment and rationale; proposed changes (If changes to the wording are suggested, they should be highlighted using 'track changes') Outcome Clean Room and Clean Air Devices Classification. Section 4 Page 91 Comment: Measurement of Particles 5μm Particle counters, which utilise laser light technology, are known to be unable to record absolute numbers and sizes of particles 2 and trying to count low levels of particles at 5μm, is subject to a high degree of uncertainty. This is reflected in the current draft of the EN ISO standard where the monitoring of 5μm particles for ISO Class 5 is not recommended. It is understood there are different views relating to measurement of 5 micron particles together with 0.5 micron particles and this has been widely discussed within the EMA. Some believe it is more appropriate to record particle concentrations at one size only, specifically at the accompanying 0.5μm size, where the total allowable number of particles is sufficiently high to negate the inaccuracies of the particle detection metrology. Others believe 5 micron particles are vectors for microorganisms as microbe carrying particles (MCPs) so measurement is important. By measuring both 0.5 micron and 5 micron particles there can be an understanding of the amount of MCPs as part of the total particle count. Real time monitoring, particularly within EU grade A zones, is the most useful approach for managing excursions 3. Most particle counters operate at a flow rate of 1ft 3 /min where the proportioned per ft 3 limit for 5μm particles is <1. This anomaly causes considerable difficulties in setting a meaningful operational limit for particles 5μm but there are no such issues if the single particle size of 0.5μm is utilised. The approach used in particle measurement should be risk and scientifically based so guidance should take account of any scientific limitations. 17/18
18 Line number(s) of the relevant text (e.g. Lines 20-23) Stakeholder number (To be completed by the Comment and rationale; proposed changes (If changes to the wording are suggested, they should be highlighted using 'track changes') Outcome Proposed change (if any): PHSS recommendation on particle measurement: It is proposed to only use 0.5 micron particle counts in classification for the not to exceed limits in classified areas. However, 5 micron particles should also be measured but as monitoring values to contribute to understanding on the state of control. 5 micron particle levels, like microflora, could be characterised and typical trends set in monitoring for any given process. 2. Humphries A. A simple guide to how aerosol particle counters work. The Cleanroom Monitor, Scottish Society for Contamination Control, December Eaton T. Annex 1 of the EC Guide to Good Manufacturing Practice (EC GGMP) and continuous particle monitoring help or hindrance for cleanroom manufacturing? European Journal of Parenteral and Pharmaceutical Sciences 2007; 12 (2): Please add more rows if needed. 18/18
Q&A summary report from PHSS Annual conference 2015; EU GMP Annex 1 revision discussion panel.
Q&A summary report from PHSS Annual conference 2015; EU GMP Annex 1 revision discussion panel. PHSS panel Discussion on questions set relating to revision of EU guidance to Good Manufacturing Practice
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationAseptic Processing Current Issues & Trends
Aseptic Processing Current Issues & Trends 1 Introduction Richard M. Johnson Member, PDA for 20+ years President & CEO since 2009 Ladies and Gentlemen, I am happy to be here with you. Senhoras e Senhores,
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationComments from: Leem (Les entreprises du Médicament)
Submission of comments on 'Guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use Comments
More informationQuality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017
Quality Systems Indian Pharmaceutical Alliance Advanced GMP Workshops 2017 Presented by Patrick Costello on November 2017 Principal Scientific Administrator Manufacturing & Quality Compliance An agency
More informationSubmission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)
11 January 2018 Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016) Comments from: Name of organisation or individual
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationEMA perspective on Quality Metrics
EMA perspective on Quality Metrics Indian Pharmaceutical Alliance Annual Congress, Mumbai India Presented by Brendan Cuddy on 24 February 2017 Head of Manufacturing and Quality Compliance, European Medicines
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationReflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances
3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental
More informationOverview of comments received on 'Draft Guideline on manufacture of the finished dosage form'
14 July 2017 EMA/CHMP/QWP/104223/2016 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form' (EMA/CHMP/QWP/245074)
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationContamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC
Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC Contamination risk levels differ in aseptic, and non-sterile and terminally sterilized
More informationEMA action plan related to the European Commission s recommendations on product information 1
14 November 2017 EMA/680018/2017 Stakeholders and Communication Division EMA action plan related to the European Commission s recommendations on product information 1 The European Medicines Agency (EMA)
More informationICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management
1 2 3 14 December 2017 EMA/CHMP/ICH/804273/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
More informationMonthly statistics report: December 2017
19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume
More informationPhEn-602 Notes # 4 J. Manfredi
PhEn-602 Notes # 4 J. Manfredi Spring 2009 1 Basic definitions Clean Room: A room in which the concentration of airborne particles is controlled and contains one or more clean zones Clean Zone: A defined
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationSingle-Use Final Fill: Benefits and Considerations
Single-Use Final Fill: Benefits and Considerations TENDÊNCIAS DE TECNOLOGIAS DE FABRICAÇÃO E ASSÉPTICA DE MEDICAMENTOS Ana Luísa Lampert Cadore Sales Specialist SU & Aseptic Process Solutions ana.cadore@merckgroup.com
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More informationPublication of Risk Management Plan (RMP) summaries:
Publication of Risk Management Plan (RMP) summaries: Analysis of the experience of the 1-year pilot phase PCWP meeting November 2015 An agency of the European Union Why produce a Summary of the Risk Management
More informationWhitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview
High temperature HEPA filtration Air filtration challenges and answers for dry heat sterilization tunnels Whitepaper Preview Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Air filtration
More informationIs it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS
Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS Agenda Annex 1 revision why? Impact of the change on the field Conclusion The Revision
More informationPlease note that these comments and the identity of the sender will be published unless a specific justified objection is received.
11.07.2017 Submission of comments on 'Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials'
More informationISO INTERNATIONAL STANDARD. Cleanrooms and associated controlled environments Part 4: Design, construction and start-up
INTERNATIONAL STANDARD ISO 14644-4 First edition 2001-04-01 Cleanrooms and associated controlled environments Part 4: Design, construction and start-up Salles propres et environnements maîtrisés apparentés
More informationGood manufacturing practices
The rules governing medicinal products in the European Union Volume 4 Good manufacturing practices Medicinal products for human and veterinary use 1998 Edition EUROPEAN COMMISSION Directorate General III
More informationPERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM
Page 1 of 24 PERFORMANCE QUALIFICATION PROTOCOL FOR HVAC SYSTEM Signing of this Performance Qualification Protocol indicates agreement with the Validation Master Plan approach of the equipment. Further
More informationSPOR data management services - high level changes
6 July 2017 EMA/551661/2016 version 3 Information Management Division Table of contents 1. Introduction... 2 2. New solutions for access and use of SPOR data... 2 2.1. RMS backward compatibility... 2 2.2.
More informationAdvanced Therapies in Europe
Advanced Therapies in Europe 1 ATMPs in Europe (2009-2017) ~ 500 clinical trials using ATMPs in EU ~ 270 ATMP classifications 18 MAAs reviewed ~ 250 scientific advice requests 9 ATMPs approved 2 3 withdrawn
More informationWhen Quality Matters. Microbial Air Samplers: Selection Criteria in Biopharma Manufacturing. Celebrating Over 50 Years In Business!
When Quality Matters Celebrating Over 50 Years In Business! Microbial Air Samplers: Selection Criteria in Biopharma Manufacturing Rev. 1.0 (Jan 2016) 1 Doc No.: TN-160104-1 Printed: January 4, 2016 Copyright
More informationDraft agreed by SWP, vswp and GMP/GDP Inspectors WG September Adopted by CVMP for release for consultation 8 November 2016
15 December 2016 EMA/CHMP/CVMP/SWP/463311/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Questions and answers on implementation of
More informationUpdate to the Manufacturing Principles for Medicinal Products
Update to the Manufacturing Principles for Medicinal Products Michel Lok, Head of Office Robyn Oatey, GMP Auditor, Medicines Office of Manufacturing Quality Therapeutic Goods Administration Introduction
More informationAnnex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119
Annex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119 February 28, 2018 Manufacture of sterile drugs (GUI-0119) Author: Health Canada Date issued: February 28, 2018 Implementation
More informationQuestions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility
15 June 2017 EMA/CVMP/ADVENT/751229/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Questions and Answers on allogenic stem cell-based products for veterinary use: Draft problem statement
More informationMedical Literature Monitoring
Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationValidation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
More informationEuropean Medicines Agency Quality Working Party, London
Europe ggmbh Adalbertstraße 9 16548 Glienicke/Berlin Germany Tel: +49 (33056) 2377-10 Fax : +49 (33056) 2377-77 Georg Roessling, PhD General Manager Senior Vice President PDA Europe http://europe.pda.org
More informationIntroductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports
24 October 2016 EMA/606369/2012 Rev.15 Procedure Management and Committees Support Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
17 December 2015 EMA/839636/2015 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Reflection paper on the chemical structure and properties criteria to be considered
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationPHCT 401 Aseptic Processes & Techniques
PHCT 401 Aseptic Processes & Techniques Principles of Aseptic Techniques Aseptic Processing Sterility Testing Laminar flow air cleaning Quality Control Tests Personnel Principles of Aseptic Techniques
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
9 November 2017 EMA/CHMP/CVMP/3Rs/83712/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Guidance
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationUNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS
DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2006-008 In Reply Refer To: 10NB UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL
More informationSemiconductor Manufacturing Facility Design
TM W W W. C E M A G. U S J U LY / A U G U S T 2 0 1 5 Semiconductor Manufacturing Facility Design Modular cleanrooms: An evolving industry ISO 14644 and biopharma monitoring Cleanrooms have a dirty little
More informationQuality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Quality Implementation Working Group on Q8, Q9 and Q10 & Current version dated June
More informationASEPTIC BIOPHARMACEUTICAL MANUFACTURING: FAQs
ASEPTIC BIOPHARMACEUTICAL MANUFACTURING: FAQs THE BIOTRAK REAL-TIME VIABLE PARTICLE COUNTER UNDERSTANDING, ACCELERATED REDUCE RISK INCREASE EFFICIENCY IMPROVE PROCESS UNDERSTANDING The BioTrak Real-Time
More informationCONTENTS 1 INTRODUCTION The Regulatory Focus on Quality Risk Management Objectives of Risk Assessment and Risk Management: The Key Concepts Key Terms in Relation to Risk and Risk Assessment Structure of
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationCompounding Aseptic Isolators (CAI) James T Wagner
Compounding Aseptic Isolators (CAI) James T Wagner jimwagner@cenvironment.com Disclaimer "Although I am a member of the USP Sterile Compounding Expert Committee, I am speaking today in my individual capacity
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationWhere Quality Meets Flexibility
Where Quality Meets Flexibility is an industry leading 503B Outsourcing Facility providing sterile and non-sterile compounding services to hospitals, surgery centers, clinics, researchers & patients nationwide.
More informationPre-accession product information linguistic review process (PALC III)
28 July 2011 EMA/48630/2011 rev. 1 Patient Health Protection Pre-accession product information linguistic review process (PALC III) Product information linguistic review process Extension of Commission
More informationSTERILE FILTRATION: PDA: A Global. Clarification Proposal Annex 1 Paragraph 113:
STERILE FILTRATION: PDA: A Global Clarification Proposal Annex 1 Paragraph 113: Focus Association on Pre-use/Poststerilization Integrity Testing Issue Paragraph 113: The integrity of the sterilised filter
More informationTests to Support Sterility Claim. Imtiaz Ahmed
Tests to Support Sterility Claim Imtiaz Ahmed Sterile Product As per TGO 77, a sterile product must comply with the requirements of the following tests: Sterility Test Bacterial Endotoxins Test Appendix
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationPIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
More informationParticulates Testing; Requirements and Challenges. Paul G. Varley, VP Development, MedImmune Ltd., Cambridge, UK
Particulates Testing; Requirements and Challenges Paul G. Varley, VP Development, MedImmune Ltd., Cambridge, UK The Simple Stuff Many antibodies form particulates Visible (and sub-visible) Particulates
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationPOSITION PAPER Moving from the MDD to the MDR
A summary of Key Changes regarding Sterile Packaging and considerations on recommended changes to standards Introduction EN ISO 11607 specifies the requirements and test methods for materials, preformed
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationEuropean Medicines Agency practical guidance on the application form for centralised type IA and IB variations
30 June 2017 EMA/233564/2014 - Rev. 2 Procedure Management and Business Support Division European Medicines Agency practical guidance on the application form for centralised This document is intended as
More informationICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management - Annexes
1 2 3 14 December 2017 EMA/CHMP/ICH/831751/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
More informationFive years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
More informationGuidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs
9 November 2017 EMA/CHMP/CVMP/3Rs/94436/2014 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guidance for individual laboratories for transfer
More informationJulie Roberts. Audit hot Topics and Regulatory Requirements
Julie Roberts Audit hot Topics and Regulatory Requirements Overview Hot Topics Examples in warning letters Tips to detecting data integrity Recent changes in regulatory requirements Hot Topics Microbial
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More information31 August Dear Dr. Bursikova,
Europe ggmbh General Manager: Georg Roessling, PhD Sr. Vice President Adalbertstraße 9 16548 Glienicke Germany Tel: +49 (33056) 2377-10 Fax: +49 (33056) 2377-77 www.pda.org OFFICERS Chair: Maik Jornitz
More informationStandard operating procedure
Standard operating procedure Title: Handling invoice payment within deadline of 30 days (Standard Payments) Status: PUBLIC Document no.: SOP/EMA/0135 Lead author Approver Effective date: 18-FEB-2015 ame:
More informationThe Guidance for Industry Manufacture of Sterile Pharmaceutical Products by Aseptic Processing - (Revised version)
The Guidance for Industry 2011 - Manufacture of Sterile Pharmaceutical Products by Aseptic Processing - (Revised version) Sterile Product GMP Committee, Japan PDA Nobuo Tateishi Chugai Pharmaceutical Co.,
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationOrange and Yellow Guides
PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationMedia Fill A Process Simution. Presented By Shikha Chauhan
Media Fill A Process Simution Presented By Shikha Chauhan 21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment,
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationDraft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
More informationTechnical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities PDA Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationMandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)
6 October 2016 EMA/CVMP/ADVENT/630299/2014 Rev.2 Committee for Medicinal Products for Veterinary Use (CVMP) Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel
More information